Industrial Scale-up and Commercialization Challenges of Redox-Responsive Drug Delivery Systems

A revolutionary development in nanomedicine, redox-responsive drug delivery systems (RRDDS) allow for site-specific drug release that is activated by intracellular redox gradients. Scale-up, repeatability, and regulatory compliance are major obstacles to the industrial translation of RRDDS, despite encouraging preclinical results. A number of complex obstacles to commercialization are examined in this chapter, such as the choice of Generally Recognized as Safe (GRAS) materials, the scalable synthesis of redox-sensitive polymers, and formulation stability in industrial settings. Key quality characteristics (CQAs) such as particle size distribution, storage stability, and redox sensitivity are prioritized. Advanced quality control methods, lyophilization, antioxidant integration, and inert-atmosphere production are described. The Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines are used to analyze the regulatory environment, paying particular attention to new international routes. Successful academic-industry partnerships and knowledge transfer approaches are demonstrated by case studies from Indian pharmaceutical businesses. The chapter concludes with a strategy plan that includes gradual market entrance, intellectual property (IP) protection, start-up incubation, and cost optimization. Bringing accuracy, safety, and efficacy to next-generation medicines, this chapter presents a comprehensive framework to guide the successful commercialization of RRDDS. This framework is provided by methodically tackling the scientific, technological, economic, and regulatory challenges that stand in the way.